John Kleckley, MD
Geriatric Medicine · Columbia, SCNPI 1356544100
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,780 of the $19,300 with a category attached, or 81.8%. Johnson & Johnson accounts for 92.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $18,140 and has fallen 97.9% since, to $385 in 2025. Among geriatric medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $201.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$18K
- AbbVie$173
- Boston Scientific$135
- Otsuka America Pharmaceutical, Inc.$133
- Pfizer$88
- Janssen Scientific Affairs, LLC$86
- plus $766 from 21 others
What the payments were for
- Speaking & faculty fees$15,78082%
- Travel & lodging$1,6599%
- Food & beverage$1,85310%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $17,918 |
| AbbVie | 8 | $173 |
| Boston Scientific | 2 | $135 |
| Otsuka America Pharmaceutical, Inc. | 5 | $133 |
| Pfizer | 5 | $88 |
| Janssen Scientific Affairs, LLC | 1 | $86 |
| GSK | 3 | $78 |
| Lundbeck LLC | 3 | $73 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Eisai Inc. | 2 | $54 |
| Abbott | 2 | $52 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Lilly USA, LLC | 3 | $49 |
| AstraZeneca | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Novo Nordisk | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Recor Medical Inc | 1 | $26 |
| Phadia US Inc. | 1 | $25 |
| Axonics, Inc. | 1 | $21 |
| Medtronic | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Merck | 1 | $17 |
| Novartis | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
| C2n Diagnostics, LLC | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,300 in reported general payments places this provider in the 95th percentile of 41 geriatric medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 255 | $144,802 |
| MounjaroTirzepatide | 38 | $44,043 |
| XareltoRivaroxaban | 43 | $34,874 |
| MyrbetriqMirabegron | 61 | $29,839 |
| Memantine Hcl | 309 | $27,024 |
| JardianceEmpagliflozin | 23 | $17,631 |
| OzempicSemaglutide | 16 | $16,978 |
| EntrestoSacubitril/Valsartan | 15 | $14,554 |
| JanuviaSitagliptin Phosphate | 19 | $9,982 |
| GemtesaVibegron | 22 | $9,830 |
| Rivastigmine | 34 | $8,731 |
| Quetiapine Fumarate | 281 | $7,337 |
| NamzaricMemantine Hcl/Donepezil Hcl | 13 | $7,233 |
| Mirabegron ErMirabegron | 11 | $7,101 |
| Donepezil Hcl | 265 | $6,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $144,802255 claims |
| Lilly USA, LLCMounjaro | $49 | $44,04338 claims |
| Johnson & JohnsonXarelto | $17,918 | $34,87443 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $29,83961 claims |
| Novo NordiskOzempic | $35 | $16,97816 claims |
| NovartisEntresto | $16 | $14,55415 claims |
| MerckJanuvia | $17 | $9,98219 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $50 | $9,83022 claims |
| AbbVieNamzaric, Synthroid | $173 | $9,55452 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $34 | $6,600530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 geriatric medicine providers in South Carolina.
Other geriatric medicine in Columbia
- Tad VennColumbia$430
- Stephanie CurryColumbia$216
- Rachelle GajadharColumbia$173
- Margaret MatthewsColumbia$136
- Craig MaylathColumbia$101
- Pooja GhaiColumbia$49
- Victor HirthColumbia$0
- Fariha SultanGreenville$6K
- Joseph GarandPiedmont$4K
- William ChildersLaurens$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.